GlassScriptPhysician profile
Patricia E Kennery
NPI 1295161016
$10,881.67
in general payments reported to CMS, 2019-2025
42 companies · $3,921 in 2025
The $3,921 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,214 · 2022: $1,372 · 2023: $2,453 · 2024: $1,921 · 2025: $3,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,196 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,195.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,840.01 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,227.76 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,004.74 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $849.70 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $633.73 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $603.72 | 2021-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $557.74 | 2021-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $414.99 | 2021-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $389.54 | 2024-2025 | Winrevair, Zerbaxa, Dificid |
| Inspire Medical Systems, INC. | $367.87 | 2024-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $337.20 | 2021-2025 | Acthar |
| Amgen INC. | $306.33 | 2021-2025 | Tezspire, Tavneos |
| Electromed, INC. | $271.05 | 2021-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $232.58 | 2021-2023 | |
| Verona Pharma, INC. | $180.62 | 2025 | Ohtuvayre |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $177.65 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $168.28 | 2023-2025 | Glassia |
| Inogen, INC. | $132.32 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Biotronik INC. | $129.90 | 2023 | Edora 8 Dr-T, Biomonitor, Acticor 7 Vr-T Dx |
| Pfizer INC. | $113.59 | 2023-2024 | |
| Pulmonx Corporation | $103.45 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Axsome Therapeutics, INC. | $83.68 | 2023-2024 | Sunosi |
| United Therapeutics Corporation | $82.54 | 2021-2023 | Tyvaso |
| Insmed, INC. | $76.76 | 2021-2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $68.75 | 2023-2024 | Jardiance, Emgality, Zepbound |
| 3b Medical, INC. | $67.50 | 2024-2025 | Luna |
| Viatris Specialty LLC | $57.72 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.20 | 2022-2024 | Xifaxan |
| Jazz Pharmaceuticals INC. | $43.62 | 2021-2022 | |
| Fisher & Paykel Healthcare INC | $43.37 | 2022 | |
| Novo Nordisk INC | $43.23 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $35.03 | 2021-2022 | |
| Vifor Pharma, INC. | $26.22 | 2025 | Zemaira |
| Alexion Pharmaceuticals, INC. | $22.94 | 2021 | |
| Abbvie INC. | $21.27 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.74 | 2023 | Quviviq |
| Advanced Respiratory, INC | $17.27 | 2021 | |
| Exact Sciences Corporation | $17.26 | 2025 | Cologuard Collection Kit |
| Kaleo, INC. | $17.04 | 2021 | |
| Gilead Sciences, INC. | $16.63 | 2021 | |
| Baxter Healthcare | $14.85 | 2023 | Hillrom - Life 2000 Ventilation System |
| Amarin Pharma, INC. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Kennery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.